Tags

Type your tag names separated by a space and hit enter

A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel.

Abstract

The effects of norgestimate triphasic (Ortho Tri-Cyclen, Tri-Ciles) and levonorgestrel triphasic (Triphasi) formulations on lipid and androgen metabolism were assessed in a study of 66 healthy women treated through six menstrual cycles. Levels of the following were measured: cholesterol and its subfractions, triglycerides, carrier lipoproteins, estradiol, testosterone, and sex hormone binding globulin (SHBG). Comparison of baseline values with values after 3 and 6 months of treatment indicated that both regimens influenced lipid and androgen metabolism. There was a statistically significant between-regimen difference in levels of high-density lipoprotein, which were favorably increased with norgestimate triphasic but reduced with levonorgestrel triphasic. Related data on SHBG showed that plasma levels of this marker of estrogen/androgen balance were increased significantly more in the norgestimate triphasic group, providing additional evidence of low androgenicity. Both regimens inhibited follicular growth to the same extent, as evidenced by low mean levels of estradiol in all on-therapy cycles; and both decreased free testosterone. Side effects in both groups were minor and characteristic of those observed with low-dose oral contraceptive agents. The results of the study support the reported safety and positive effects of norgestimate on lipid and androgen metabolism, in comparison with a levonorgestrel-containing combined oral contraceptive.

Authors+Show Affiliations

Hôpital Saint-Louis, Paris, France.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

1324555

Citation

Janaud, A, et al. "A Comparison Study of Lipid and Androgen Metabolism With Triphasic Oral Contraceptive Formulations Containing Norgestimate or Levonorgestrel." Acta Obstetricia Et Gynecologica Scandinavica. Supplement, vol. 156, 1992, pp. 33-8.
Janaud A, Rouffy J, Upmalis D, et al. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand Suppl. 1992;156:33-8.
Janaud, A., Rouffy, J., Upmalis, D., & Dain, M. P. (1992). A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstetricia Et Gynecologica Scandinavica. Supplement, 156, 33-8.
Janaud A, et al. A Comparison Study of Lipid and Androgen Metabolism With Triphasic Oral Contraceptive Formulations Containing Norgestimate or Levonorgestrel. Acta Obstet Gynecol Scand Suppl. 1992;156:33-8. PubMed PMID: 1324555.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. AU - Janaud,A, AU - Rouffy,J, AU - Upmalis,D, AU - Dain,M P, PY - 1992/1/1/pubmed PY - 1992/1/1/medline PY - 1992/1/1/entrez KW - Androgens--analysis KW - Biology KW - Comparative Studies KW - Contraception KW - Contraceptive Agents, Estrogen KW - Contraceptive Agents, Female--side effects KW - Contraceptive Agents, Progestin--side effects KW - Contraceptive Agents--side effects KW - Contraceptive Methods--side effects KW - Contraceptive Usage KW - Data Analysis KW - Developed Countries KW - Endocrine System KW - Ethinyl Estradiol KW - Europe KW - Examinations And Diagnoses KW - Family Planning KW - France KW - Hormones KW - Laboratory Examinations And Diagnoses KW - Levonorgestrel--side effects KW - Lipid Metabolic Effects KW - Lipids KW - Mediterranean Countries KW - Method Acceptability KW - Norgestimate--side effects KW - Oral Contraceptives, Combined--side effects KW - Oral Contraceptives, Phasic--side effects KW - Oral Contraceptives--side effects KW - Physiology KW - Research Methodology KW - Studies KW - Western Europe SP - 33 EP - 8 JF - Acta obstetricia et gynecologica Scandinavica. Supplement JO - Acta Obstet Gynecol Scand Suppl VL - 156 N2 - The effects of norgestimate triphasic (Ortho Tri-Cyclen, Tri-Ciles) and levonorgestrel triphasic (Triphasi) formulations on lipid and androgen metabolism were assessed in a study of 66 healthy women treated through six menstrual cycles. Levels of the following were measured: cholesterol and its subfractions, triglycerides, carrier lipoproteins, estradiol, testosterone, and sex hormone binding globulin (SHBG). Comparison of baseline values with values after 3 and 6 months of treatment indicated that both regimens influenced lipid and androgen metabolism. There was a statistically significant between-regimen difference in levels of high-density lipoprotein, which were favorably increased with norgestimate triphasic but reduced with levonorgestrel triphasic. Related data on SHBG showed that plasma levels of this marker of estrogen/androgen balance were increased significantly more in the norgestimate triphasic group, providing additional evidence of low androgenicity. Both regimens inhibited follicular growth to the same extent, as evidenced by low mean levels of estradiol in all on-therapy cycles; and both decreased free testosterone. Side effects in both groups were minor and characteristic of those observed with low-dose oral contraceptive agents. The results of the study support the reported safety and positive effects of norgestimate on lipid and androgen metabolism, in comparison with a levonorgestrel-containing combined oral contraceptive. SN - 0300-8835 UR - https://www.unboundmedicine.com/medline/citation/1324555/A_comparison_study_of_lipid_and_androgen_metabolism_with_triphasic_oral_contraceptive_formulations_containing_norgestimate_or_levonorgestrel_ DB - PRIME DP - Unbound Medicine ER -